ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
67.54
-1.19 (-1.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close68.73
Open67.91
Bid0.00 x 800
Ask0.00 x 800
Day's Range67.33 - 69.25
52 Week Range60.27 - 124.22
Volume815,480
Avg. Volume960,661
Market Cap7.196B
Beta (3Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-7.87
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est125.22
Trade prices are not sourced from all markets
  • Business Wire11 days ago

    Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel in Las Vegas, Nevada.

  • Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
    Zacks12 days ago

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    Sector ETF report for PBE

  • Can Pfizer Leap Over the Competition With This Potential Blockbuster?
    Motley Fool12 days ago

    Can Pfizer Leap Over the Competition With This Potential Blockbuster?

    It's been nearly seven years since the FDA refused to approve tafamidis's first new drug application, and the field is a lot more crowded now.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ALNY are favorable, with net inflows of $4.32 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks
    Investor's Business Daily13 days ago

    How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks

    Dow Jones component Pfizer gained approval Monday for a drug that treats a rare heart disease — potentially rivaling new drugs from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.

  • Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come
    Motley Fool14 days ago

    Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come

    Additional drug approvals and launches are on the way.

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of ALNY earnings conference call or presentation 1-May-19 12:30pm GMT

    Q1 2019 Alnylam Pharmaceuticals Inc Earnings Call

  • Alnylam Pharmaceuticals Put Buyers Take Profits During Slide
    Schaeffer's Investment Research16 days ago

    Alnylam Pharmaceuticals Put Buyers Take Profits During Slide

    The biopharma stock is selling off on Sanofi news

  • Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
    GuruFocus.com17 days ago

    Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks

    Fund releases 1st-quarter portfolio

  • Regeneron (REGN) to Report Q1 Earnings: What's in Store?
    Zacks17 days ago

    Regeneron (REGN) to Report Q1 Earnings: What's in Store?

    Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter results.

  • Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1
    Zacks18 days ago

    Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1

    Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.

  • Can Alnylam Pharmaceuticals Stock Start Climbing Again?
    Motley Fool18 days ago

    Can Alnylam Pharmaceuticals Stock Start Climbing Again?

    Investors are starting to wonder if there's anything that can lift this stock higher.

  • Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript
    Motley Fool18 days ago

    Alnylam Pharmaceuticals Inc (ALNY) Q1 2019 Earnings Call Transcript

    ALNY earnings call for the period ending March 31, 2019.

  • Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
    Zacks18 days ago

    Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

    Alnylam (ALNY) delivered earnings and revenue surprises of 22.83% and 51.68%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Alnylam: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.73. Losses, adjusted for stock option expense, were $1.42 per share. The results topped Wall Street expectations. ...

  • Business Wire19 days ago

    Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity

    − Achieved First Quarter 2019 ONPATTRO® Global Net Product Revenues of $26.3 Million with Over 400 Patients on Commercial Product Worldwide –

  • ACCESSWIRE19 days ago

    Alnylam Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Alnylam Pharmaceuticals, Inc. (EXCHANGE: ALNY ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 1, 2019 at 8:30 ...

  • Business Wire19 days ago

    Alnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran)

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced that it has made substantial progress in the global commercialization of ONPATTRO for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The Company has now completed definitive value-based agreements (VBAs) with 10 commercial payers in the United States. With 10 VBAs completed with commercial payers in the U.S., we’re fulfilling our commitment that ONPATTRO is reimbursed based on its ability to deliver outcomes in the real-world setting comparable to those demonstrated in clinical trials,” said Barry Greene, President of Alnylam.

  • Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
    Zacks24 days ago

    Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

    The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

  • Business Wire26 days ago

    Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2019 on Wednesday, May 1, 2019, before the U.S. financial markets open. To access the call, please dial 800-289-0438 (domestic) or 323-794-2423 (international) five minutes prior to the start time and refer to conference ID 4935120. To access the replay, please dial 888-203-1112 (domestic) or 719-457-0820 (international) and refer to conference ID 4935120.

  • This Is Why You Shouldn’t Count Regeneron Stock Out
    InvestorPlace27 days ago

    This Is Why You Shouldn’t Count Regeneron Stock Out

    For many healthcare stocks, April 2019 has been like tech's December 2018. Just 19% of healthcare issues are above their 50-day moving averages. Blame presidential candidate Bernie Sanders. Or blame the Democratic House, which has been holding hearings on a variety of ideas for cutting drug costs. Congress may end the practice of patent "gaming," in which drug companies make small tweaks to drugs in order to extend patent protection.Source: Shutterstock But whatever Congress does, it shouldn't impact Regeneron Pharmaceuticals (NASDAQ:REGN) to the degree it has -- Regeneron stock has plunged nearly 20% from over $400 per share on April 9 to an April 22 opening price of $333. Regeneron's MethodI have long been a fan of Regeneron stock. While most drug companies tie their futures to specific cures, Regeneron has always been focused on their methods for finding drugs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThese include Velocisuite, which offers fast manipulation of mouse DNA, and TRAP, a general method for developing enzyme blockers. Methods mean Regeneron's pipeline can be constantly renewed for a variety of conditions, from cancer to pulmonary disease to chronic pain.Methods matter. Methods get companies ahead of trends.Regeneron doesn't just know this in its research strategy but in its investment strategy. This is evidenced by a recent $800 million deal with Alnylam (NASDAQ:ALNY) to work on RNA interference, controlling how genes are expressed by interfering with messenger RNA that turns DNA sequences into traits.If Alnylam were Regeneron's only big bet, I wouldn't be listening to bullish forecasts about it. But it's not. Regeneron has development deals with many other companies, including Sanofi (NASDAQ:SNY) and Bluebird (NASDAQ:BLUE), because its gene manipulation methodology can bring drugs to markets faster. * 10 High-Yielding Dividend Stocks That Won't Wilt By having a drug development methodology and cash to spend with companies with specific therapies in mind, Regeneron investors get the ability to spread their bet across many therapies and approaches. Drugs Out of FashionUnfortunately, that's not how Regeneron is valued. Instead, analysts follow the fate of specific Regeneron cures in the market, acting like competition for a single "blockbuster" is going to sink REGN stock.Right now, this makes REGN stock a great bargain. Regeneron's return on equity is 28%. Its price-to-earnings ratio is below 16, with investors paying $333 for over $21 per share of earnings. That's bargain territory.Regeneron is expected to earn $5.39 per share on revenues of $1.72 billion when it next reports May 7, but it has lately made a habit of beating earnings estimates, often by a lot. Analysts are whispering it might beat estimates this quarter by 14 cents, but in the last quarter, it beat estimates by $1.24, and the current estimates are lower. The Bottom Line on Regeneron StockI take a long-term view on stocks, looking for the leading edge of technology, where the value added to society is greatest.The current decade has been all about the cloud, which has brought enormous amounts of computing power to desktops and even mobile platforms.The next decade will be about using this power to turn DNA into a computer language that can be read and manipulated. A research methodology can act like an old-style PC operating system in this worldThis is not a guarantee of long-term success. It only means a company is playing the new game in the right way. That's what I like about Regeneron stock. It has method amid the madness.Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in REGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post This Is Why You Shouldn't Count Regeneron Stock Out appeared first on InvestorPlace.

  • Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)
    Insider Monkeylast month

    Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
    Zackslast month

    Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

    Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

  • Is Alnylam Pharmaceuticals a Buy Now?
    Motley Foollast month

    Is Alnylam Pharmaceuticals a Buy Now?

    Everything's falling into place for the pioneer of RNA interference.